In a recent clinical trials (NCT02650999), 12 patients with B-cell lymphomas who were either refractory or relapsed after CD19 CAR-T cell therapy were treated with anti-PD1 agent pembrolizumab, and best ORR after pembrolizumab was 25% (3 of 12 patients; 1 CR; 2 PR); and 4 of 12 (33%) patients had clinical benefit and an increase in percentage of CAR-T cells (111). The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.